NCT06592599 2026-02-10
Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
Stanford University
Phase 2 Recruiting
Clinical Trials
17 trialsNCT07136519 2025-08-22
Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma
Affiliated Hospital of Guangdong Medical University
Phase 2 Not yet recruiting
NCT07110558 2025-08-07
PUPA
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT05147844 2025-07-14
Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
Xinqiao Hospital of Chongqing
Phase 2 Recruiting
NCT06987123 2025-05-23
TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06912711 2025-05-21
TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT04517214 2025-04-02
Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma
Fudan University
Phase 2 Active not recruiting
NCT06851247 2025-02-28
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
Sun Yat-sen University
Phase 2 Recruiting
NCT04996758 2024-12-12
Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)
Sun Yat-sen University
Phase 2 Completed
NCT06323239 2024-08-20
SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Recruiting
NCT05813626 2023-04-14
Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT05229315 2023-04-13
PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT04405622 2023-02-06
Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.
Sun Yat-sen University
Phase 2 Unknown
NCT05484375 2022-08-02
Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2 Not yet recruiting
NCT04992988 2021-08-20
Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial
Cancer Hospital of Guangxi Medical University
Phase 2 Unknown
NCT04955886 2021-07-09
Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma
Fujian Cancer Hospital
Phase 2 Unknown
NCT04447326 2020-06-25
Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma
First Affiliated Hospital of Guangxi Medical University
Phase 2 Not yet recruiting